Home › Companies › VOYAGER THERAPEUTICS INC. › 2024-2025

VOYAGER THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and VOYAGER THERAPEUTICS INC.’s Form 8-K, filed 2025-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

10Reported items
146Asset managers
1,302Fund votes
2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VOYAGER THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by VOYAGER THERAPEUTICS INC.

These tallies are VOYAGER THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VOYAGER THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Grace E. Colón, Ph.D.	38,209,235	--	--	1,688,859	8,531,070	Majority: yes
Elect Director: Catherine J. Mackey, Ph.D.	38,216,364	--	--	1,681,730	8,531,070	Majority: yes
Elect Director: Glenn Pierce, M.D., Ph.D.	38,123,609	--	--	1,774,485	8,531,070	Majority: yes
Elect Director: George Scangos, Ph.D.	33,177,695	--	--	6,720,399	8,531,070	Majority: yes
Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.	37,755,432	2,034,622	108,040	--	8,531,070	Majority: yes
Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2025.	48,137,216	249,172	42,776	--	--	Majority: yes
Voyager's stockholders approved the 2025 Stock Incentive Plan.	28,582,188	11,275,604	40,302	--	8,531,070	Majority: yes
Voyager's stockholders approved the Amended and Restated 2015 Employee Stock Purchase Plan.	36,532,540	3,326,824	38,730	--	8,531,070	Majority: yes

Source: VOYAGER THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-05 — read the filing on EDGAR.

How asset managers voted at the VOYAGER THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 146 asset managers that disclosed a VOYAGER THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VOYAGER THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 37,755,432AGAINST: 2,034,622

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”): 37,755,432 for, 2,034,622 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 68% for, 4% against (72% of the company cast a for/against vote).

The 144 asset managers below cast 95% of the shares they voted on this item FOR (27,670,547 for, 1,564,608 against).

FOR 94%

FOR: 27,670,547 (94.5%)AGAINST: 1,564,608 (5.3%)ABSTAIN: 60,505 (0.2%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
ARMISTICE CAPITAL, LLC	4,442,185	0	For
EcoR1 Capital, LLC	3,917,546	0	For
BlackRock	3,659,612	522	For
Vanguard	3,065,504	0	For
FARALLON CAPITAL MANAGEMENT LLC	2,570,700	0	For
Erste Asset Management GmbH	1,116,793	0	For
T. Rowe Price	1,063,213	0	For
Fidelity	990,182	0	For
Dimensional	0	982,620	Against
GEODE CAPITAL MANAGEMENT, LLC	940,418	0	For
Vestal Point Capital, LP	925,991	0	For
State Street	858,666	238	For
GREAT POINT PARTNERS LLC	626,275	0	For
Charles Schwab	275,142	0	For
American Century	0	262,928	Against
FIDUCIARY TRUST CO	259,397	0	For
JPMorgan	251,968	0	For
Northern Trust	222,007	0	For
Wellington	184,176	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	183,738	0	For
MFS	183,738	0	For
AQR	139,949	0	For
Nuveen	108,789	0	For
TIAA	107,849	0	For
Equitable	95,338	0	For

Showing the 25 largest of 144 asset managers. See all 144 in the interactive database.

2. To approve the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 36,532,540AGAINST: 3,326,824

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders approved the Amended and Restated 2015 Employee Stock Purchase Plan.”): 36,532,540 for, 3,326,824 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 66% for, 6% against (72% of the company cast a for/against vote).

The 49 asset managers below cast 99.8% of the shares they voted on this item FOR (9,917,297 for, 12,240 against).

FOR 99.8%

FOR: 9,917,297 (99.9%)AGAINST: 12,240 (0.1%)

Largest asset managers voting on “To approve the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan.” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,037,000	0	For
BlackRock	2,160,123	0	For
Erste Asset Management GmbH	1,116,793	0	For
Fidelity	903,204	0	For
Dimensional	841,759	0	For
T. Rowe Price	423,498	0	For
MFS	183,738	0	For
Charles Schwab	137,571	0	For
American Century	130,899	0	For
TIAA	107,849	0	For
Equitable	95,338	0	For
BRIDGEWAY FUNDS INC	83,181	0	For
QUANTITATIVE MASTER SERIES LLC	76,599	0	For
WisdomTree	57,491	0	For
EA Series Trust	48,265	0	For
Goldman Sachs	44,721	0	For
Lincoln Financial	39,337	0	For
Allspring	38,980	0	For
John Hancock	34,624	0	For
MASTER INVESTMENT PORTFOLIO	29,960	0	For
Northern Trust	28,118	0	For
AIG/SunAmerica	22,537	0	For
Columbia Threadneedle	22,320	0	For
Brighthouse	9,134	12,240	Against
Pacific Life	21,272	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Catherine J. Mackey, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 38,216,364WITHHELD: 1,681,730

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Catherine J. Mackey, Ph.D.”): 38,216,364 for, 1,681,730 withheld, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 69% for, 3% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (7,935,180 for, 0 against).

FOR 80%ABSTAIN 20%

FOR: 7,935,180 (79.9%)ABSTAIN: 1,994,357 (20.1%)

Largest asset managers voting on “To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockh” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,037,000	0	For
BlackRock	2,160,123	0	For
Erste Asset Management GmbH	0	1,116,793	Abstain
Fidelity	903,204	0	For
Dimensional	0	841,759	Abstain
T. Rowe Price	423,498	0	For
MFS	183,738	0	For
Charles Schwab	137,571	0	For
American Century	130,899	0	For
TIAA	107,849	0	For
Equitable	95,338	0	For
BRIDGEWAY FUNDS INC	83,181	0	For
QUANTITATIVE MASTER SERIES LLC	76,599	0	For
WisdomTree	57,491	0	For
EA Series Trust	48,265	0	For
Goldman Sachs	44,721	0	For
Lincoln Financial	34,100	5,237	For
Allspring	38,980	0	For
John Hancock	33,263	1,361	For
MASTER INVESTMENT PORTFOLIO	29,960	0	For
Northern Trust	28,118	0	For
AIG/SunAmerica	22,537	0	For
Columbia Threadneedle	22,320	0	For
Brighthouse	9,134	12,240	Abstain
Pacific Life	21,272	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: George Scangos, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%

FOR: 33,177,695WITHHELD: 6,720,399

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: George Scangos, Ph.D.”): 33,177,695 for, 6,720,399 withheld, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 60% for, 12% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (8,179,279 for, 0 against).

FOR 82%ABSTAIN 18%

FOR: 8,179,279 (82.4%)ABSTAIN: 1,750,258 (17.6%)

Largest asset managers voting on “To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockh” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,037,000	0	For
BlackRock	2,160,123	0	For
Erste Asset Management GmbH	1,116,793	0	For
Fidelity	903,204	0	For
Dimensional	0	841,759	Abstain
T. Rowe Price	423,498	0	For
MFS	0	183,738	Abstain
Charles Schwab	137,571	0	For
American Century	0	130,899	Abstain
TIAA	107,849	0	For
Equitable	54,768	40,570	For
BRIDGEWAY FUNDS INC	0	83,181	Abstain
QUANTITATIVE MASTER SERIES LLC	76,599	0	For
WisdomTree	0	57,491	Abstain
EA Series Trust	0	48,265	Abstain
Goldman Sachs	0	44,721	Abstain
Lincoln Financial	0	39,337	Abstain
Allspring	0	38,980	Abstain
John Hancock	15,964	18,660	Abstain
MASTER INVESTMENT PORTFOLIO	29,960	0	For
Northern Trust	0	28,118	Abstain
AIG/SunAmerica	0	22,537	Abstain
Columbia Threadneedle	22,320	0	For
Brighthouse	0	21,374	Abstain
Pacific Life	21,272	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Glenn Pierce, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 38,123,609WITHHELD: 1,774,485

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Glenn Pierce, M.D., Ph.D.”): 38,123,609 for, 1,774,485 withheld, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 69% for, 3% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (9,051,973 for, 0 against).

FOR 91%9%

FOR: 9,051,973 (91.2%)ABSTAIN: 877,564 (8.8%)

Largest asset managers voting on “To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockh” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,037,000	0	For
BlackRock	2,160,123	0	For
Erste Asset Management GmbH	1,116,793	0	For
Fidelity	903,204	0	For
Dimensional	0	841,759	Abstain
T. Rowe Price	423,498	0	For
MFS	183,738	0	For
Charles Schwab	137,571	0	For
American Century	130,899	0	For
TIAA	107,849	0	For
Equitable	95,338	0	For
BRIDGEWAY FUNDS INC	83,181	0	For
QUANTITATIVE MASTER SERIES LLC	76,599	0	For
WisdomTree	57,491	0	For
EA Series Trust	48,265	0	For
Goldman Sachs	44,721	0	For
Lincoln Financial	34,100	5,237	For
Allspring	38,980	0	For
John Hancock	33,263	1,361	For
MASTER INVESTMENT PORTFOLIO	29,960	0	For
Northern Trust	28,118	0	For
AIG/SunAmerica	22,537	0	For
Columbia Threadneedle	22,320	0	For
Brighthouse	9,134	12,240	Abstain
Pacific Life	21,272	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

6. To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Grace E. Colon, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 38,209,235WITHHELD: 1,688,859

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Elect Director: Grace E. Colón, Ph.D.”): 38,209,235 for, 1,688,859 withheld, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 69% for, 3% withheld (72% of the company cast a for/withheld vote).

The 49 asset managers below cast 88% of the shares they voted on this item FOR (7,935,180 for, 1,116,793 against).

FOR 80%11%9%

FOR: 7,935,180 (79.9%)AGAINST: 1,116,793 (11.2%)ABSTAIN: 877,564 (8.8%)

Largest asset managers voting on “To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockh” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	3,037,000	0	0	For
BlackRock	2,160,123	0	0	For
Erste Asset Management GmbH	0	1,116,793	0	Against
Fidelity	903,204	0	0	For
Dimensional	0	0	841,759	Abstain
T. Rowe Price	423,498	0	0	For
MFS	183,738	0	0	For
Charles Schwab	137,571	0	0	For
American Century	130,899	0	0	For
TIAA	107,849	0	0	For
Equitable	95,338	0	0	For
BRIDGEWAY FUNDS INC	83,181	0	0	For
QUANTITATIVE MASTER SERIES LLC	76,599	0	0	For
WisdomTree	57,491	0	0	For
EA Series Trust	48,265	0	0	For
Goldman Sachs	44,721	0	0	For
Lincoln Financial	34,100	0	5,237	For
Allspring	38,980	0	0	For
John Hancock	33,263	0	1,361	For
MASTER INVESTMENT PORTFOLIO	29,960	0	0	For
Northern Trust	28,118	0	0	For
AIG/SunAmerica	22,537	0	0	For
Columbia Threadneedle	22,320	0	0	For
Brighthouse	9,134	0	12,240	Abstain
Pacific Life	21,272	0	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

7. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 48,137,216AGAINST: 249,172

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 48,137,216 for, 249,172 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 87% for, 0.5% against (87% of the company cast a for/against vote).

The 49 asset managers below cast 99.5% of the shares they voted on this item FOR (9,869,032 for, 48,265 against).

FOR 99.3%

FOR: 9,869,032 (99.4%)AGAINST: 48,265 (0.5%)ABSTAIN: 12,240 (0.1%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	3,037,000	0	0	For
BlackRock	2,160,123	0	0	For
Erste Asset Management GmbH	1,116,793	0	0	For
Fidelity	903,204	0	0	For
Dimensional	841,759	0	0	For
T. Rowe Price	423,498	0	0	For
MFS	183,738	0	0	For
Charles Schwab	137,571	0	0	For
American Century	130,899	0	0	For
TIAA	107,849	0	0	For
Equitable	95,338	0	0	For
BRIDGEWAY FUNDS INC	83,181	0	0	For
QUANTITATIVE MASTER SERIES LLC	76,599	0	0	For
WisdomTree	57,491	0	0	For
EA Series Trust	0	48,265	0	Against
Goldman Sachs	44,721	0	0	For
Lincoln Financial	39,337	0	0	For
Allspring	38,980	0	0	For
John Hancock	34,624	0	0	For
MASTER INVESTMENT PORTFOLIO	29,960	0	0	For
Northern Trust	28,118	0	0	For
AIG/SunAmerica	22,537	0	0	For
Columbia Threadneedle	22,320	0	0	For
Brighthouse	9,134	0	12,240	Abstain
Pacific Life	21,272	0	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

8. To approve the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.

COMPENSATIONMajority of the votes cast: yes

72% Majority: yes · of votes cast

FOR 72%AGAINST 28%

FOR: 28,582,188AGAINST: 11,275,604

VOYAGER THERAPEUTICS INC.’s own tally for this item (“Voyager's stockholders approved the 2025 Stock Incentive Plan.”): 28,582,188 for, 11,275,604 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,336,446 outstanding shares: 51.7% for, 20% against (72% of the company cast a for/against vote).

The 47 asset managers below cast 74% of the shares they voted on this item FOR (6,468,068 for, 2,326,373 against).

FOR 74%AGAINST 26%

FOR: 6,468,068 (73.5%)AGAINST: 2,326,373 (26.5%)

Largest asset managers voting on “To approve the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,037,000	0	For
BlackRock	2,160,123	0	For
Fidelity	820,604	82,600	For
Dimensional	0	841,759	Against
T. Rowe Price	0	423,498	Against
MFS	0	183,738	Against
Charles Schwab	137,571	0	For
American Century	0	130,899	Against
TIAA	0	107,849	Against
Equitable	52,076	43,262	For
BRIDGEWAY FUNDS INC	0	83,181	Against
QUANTITATIVE MASTER SERIES LLC	76,599	0	For
WisdomTree	0	57,491	Against
EA Series Trust	48,265	0	For
Goldman Sachs	0	44,721	Against
Lincoln Financial	0	39,337	Against
Allspring	0	38,980	Against
John Hancock	0	34,624	Against
MASTER INVESTMENT PORTFOLIO	29,960	0	For
Northern Trust	0	28,118	Against
AIG/SunAmerica	0	22,537	Against
Columbia Threadneedle	0	22,320	Against
Brighthouse	12,240	9,134	For
Pacific Life	21,272	0	For
Bridge Builder Trust	20,559	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

9. Approve Omnibus Stock Plan

COMPENSATION

98% fund support · no official result

FOR 98%

The 2 asset managers below cast 98% of the shares they voted on this item FOR (1,116,793 for, 18,303 against).

FOR: 1,116,793 (98.4%)AGAINST: 18,303 (1.6%)

Largest asset managers voting on “Approve Omnibus Stock Plan” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Erste Asset Management GmbH	1,116,793	0	0	0	For
FORUM FUNDS II	0	18,303	0	0	Against

10. Say on pay

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

95% Majority: yes · of votes cast

FOR 95%

FOR: 37,755,432AGAINST: 2,034,622

The 2 asset managers below cast 100% of the shares they voted on this item FOR (500 for, 0 against).

FOR 100%

FOR: 500 (100.0%)

Largest asset managers voting on “Say on pay” at VOYAGER THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	500	0	0	0	For
Ikarian Capital, LLC	0	0	0	0	--

Largest VOYAGER THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of VOYAGER THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 55,336,446 shares outstanding at the time of that meeting.

Top VOYAGER THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	ARMISTICE CAPITAL, LLC	8.03%
2	EcoR1 Capital, LLC	7.08%
3	BlackRock	6.61%
4	Vanguard	5.54%
5	FARALLON CAPITAL MANAGEMENT LLC	4.65%
6	Erste Asset Management GmbH	2.02%
7	T. Rowe Price	1.92%
8	Fidelity	1.79%
9	Dimensional	1.78%
10	GEODE CAPITAL MANAGEMENT, LLC	1.70%

Reported VOYAGER THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VOYAGER THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	9.78%	13F
Integrated Core Strategies (US) LLC	6.03%	13G
Vanguard Group	5.80%	13F
Dimensional Fund Advisors	2.70%	13F
Geode Capital	2.00%	13F
State Street	1.63%	13F
T. Rowe Price	1.12%	13F
Northern Trust	0.74%	13F
Morgan Stanley	0.69%	13F
Wellington Management	0.46%	13F

Percentages above are of 55,336,446 shares outstanding, as reported by VOYAGER THERAPEUTICS INC. on its Form 10-Q dated 2025-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VOYAGER THERAPEUTICS INC.’s 10-Q dated 2025-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VOYAGER THERAPEUTICS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 146 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,302 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VOYAGER THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-05.

VOYAGER THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.